Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month.

Metadata
Provider: 
GlobeNewswire, Inc.GlobeNewswire, Inc.
Retrieved on: 
Monday, April 1, 2024
Information
Tags: 
FACC, Weill Cornell Medicine, Professor, Safety, NewYork-Presbyterian Hospital, Paroxysmal attack, Paroxysmal supraventricular tachycardia, Efficacy, RAPID, American College, Sinus rhythm, Hospital, Division, Signs and symptoms, Conversion, Pharmaceutical industry
Geotags: 
MONTREAL, QUEBEC, CA, GEORGIA, CHARLOTTE, BERLIN, GERMANY
⚠ partially generated by AI ↴
Organisation: 
MILESTONE PHARMACEUTICALS, MILESTONE PHARMACEUTICALS INC.
Summary
Key Points: 
  • MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month.
  • The company will deliver oral and poster presentations at the American College of Cardiology annual meeting (ACC24) , to be held April 6-8th in Atlanta, Georgia, and a poster presentation at the annual meeting of the European Heart Rhythm Association (EHRA) , to be held April 7-9th in Berlin, Germany.
  • The presentations will be available following the embargo at https://MilestonePharma.com .
  • Multi-Center, Open-Label Study of the Efficacy and Safety of Etripamil Nasal Spray Self-Administered For Multiple Episodes of Symptomatic Supraventricular Tachycardia Without Supervision (Phase 3, NODE-303)
    James Ip, M.D., Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital
    Symptom-prompted, Self-administered Intranasal Etripamil for Termination of Paroxysmal Supraventricular Tachycardia in the RAPID Study: Relationship Among Etripamil-Induced Reduction in Tachycardia Rates, Conversion to Sinus Rhythm, and Improvement in Patient Symptoms
    James Ip, M.D., Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital
    Characterising paroxysmal supraventricular tachycardia episodes by patient-perceived episode duration, symptoms, and severity: longitudinal patient-reported outcomes
    David Bharucha, M.D., Ph.D., FACC, Chief Medical Officer of Milestone Pharmaceuticals, Inc.


MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month. The company will deliver oral and poster presentations at the American College of Cardiology annual meeting (ACC24), to be held April 6-8th in Atlanta, Georgia, and a poster presentation at the annual meeting of the European Heart Rhythm Association (EHRA), to be held April 7-9th in Berlin, Germany. The presentations will be available following the embargo at https://MilestonePharma.com.

ACC Presentation Details:
 
Oral Presentation Title:   Multi-Center, Open-Label Study of the Efficacy and Safety of Etripamil Nasal Spray Self-Administered For Multiple Episodes of Symptomatic Supraventricular Tachycardia Without Supervision (Phase 3, NODE-303)
Presenter:   James Ip, M.D., Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital
Date and time:   Monday, April 8, 2024, 11:36 – 11:46 a.m. EDT
     
Poster Presentation Title:   Symptom-prompted, Self-administered Intranasal Etripamil for Termination of Paroxysmal Supraventricular Tachycardia in the RAPID Study: Relationship Among Etripamil-Induced Reduction in Tachycardia Rates, Conversion to Sinus Rhythm, and Improvement in Patient Symptoms
Presenter:   James Ip, M.D., Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital
Date and time:   Sunday, April 7, 2024, 12:15 – 1:00 p.m. EDT
     
EHRA Presentation Details:
     
Poster Presentation Title:   Characterising paroxysmal supraventricular tachycardia episodes by patient-perceived episode duration, symptoms, and severity: longitudinal patient-reported outcomes
Presenter:   David Bharucha, M.D., Ph.D., FACC, Chief Medical Officer of Milestone Pharmaceuticals, Inc.
Date and time:   Sunday, April 7, 2024, 10:15 a.m. CET
     

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat highly symptomatic episodic attacks associated with PSVT and AFib-RVR.

Contact:

Kim Fox, Vice President, Communications
[email protected]

Investor Relations

Chris Calabrese, [email protected] 
Kevin Gardner, [email protected]

 


Primary Logo
Copyright: 
2024 GlobeNewswire, Inc.. All Rights Reserved.